Medical Oncology

, Volume 26, Issue 2, pp 202–209

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

  • Janice P. Dutcher
  • Paul de Souza
  • David McDermott
  • Robert A. Figlin
  • Anna Berkenblit
  • Alexandra Thiele
  • Mizue Krygowski
  • Andrew Strahs
  • Jay Feingold
  • Gary Hudes
Original Paper

DOI: 10.1007/s12032-009-9177-0

Cite this article as:
Dutcher, J.P., de Souza, P., McDermott, D. et al. Med Oncol (2009) 26: 202. doi:10.1007/s12032-009-9177-0

Abstract

Purpose Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to assess the influence of tumor histology on outcome of patients treated with temsirolimus (Torisel™) or interferon-α (IFN). Patients and methods Patients with ARCC including clear cell and other types such as papillary and chromophobe histologies received either IFN (3 million units [MU] subcutaneously three times weekly, escalating to 18 MU) or temsirolimus (25 mg intravenously weekly). Results Approximately 80% of patients had clear cell and 20% of patients had other histologies, the majority of which were papillary. Patients with clear cell and other RCC histologies, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In contrast, patients with other RCC histologies, treated with IFN, demonstrated shorter median overall and progression-free survival than patients with clear cell RCC. Hazard ratios for death for treatment with temsirolimus versus IFN were less than 1 for patients regardless of tumor histology. For patients treated with temsirolimus, 59% with clear cell and 68% with other RCC histologies experienced tumor reductions. For patients treated with IFN, 35% with clear cell and 14% with other RCC histologies had tumor reductions. However, temsirolimus did not appear to improve the objective response rate compared to IFN. Temsirolimus resulted in a superior clinical benefit rate compared with IFN, regardless of tumor histology. Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC.

Keywords

Temsirolimus Interferon-α Renal cell carcinoma Tumor histology 

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Janice P. Dutcher
    • 1
  • Paul de Souza
    • 2
  • David McDermott
    • 3
  • Robert A. Figlin
    • 4
  • Anna Berkenblit
    • 5
  • Alexandra Thiele
    • 5
  • Mizue Krygowski
    • 5
  • Andrew Strahs
    • 5
  • Jay Feingold
    • 5
  • Gary Hudes
    • 6
  1. 1.Montefiore Medical Center-North Division/New York Medical CollegeBronxUSA
  2. 2.Department of Medical OncologySt. George HospitalKogarahAustralia
  3. 3.Department of OncologyBeth Israel Deaconess Medical CenterBostonUSA
  4. 4.Division of Medical Oncology and Experimental TherapeuticsCity of Hope Comprehensive Cancer CenterDuarteUSA
  5. 5.Wyeth ResearchCambridgeUSA
  6. 6.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations